Latash Investments’s Aquestive Therapeutics AQST Stock Holding History

Latash Investments’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Hold	243,134	–	–	0.74%	7
2026 Q1	$1.01M	Hold	243,134	–	–	0.78%	6
2025 Q4	$1.57M	Hold	243,134	–	–	1.05%	6
2025 Q3	$1.36M	Hold	243,134	–	–	0.99%	6
2025 Q2	$805K	Hold	243,134	–	–	0.62%	8
2025 Q1	$705K	Hold	243,134	–	–	0.58%	9
2024 Q4	$866K	Hold	243,134	–	–	0.68%	9
2024 Q3	$1.21M	Hold	243,134	–	–	1.11%	8
2024 Q2	$632K	Hold	243,134	–	–	0.51%	12
2024 Q1	$1.04M	Hold	243,134	–	–	0.74%	10
2023 Q4	$491K	Hold	243,134	–	–	0.35%	14
2023 Q3	$372K	Hold	243,134	–	–	0.32%	15
2023 Q2	$401K	Hold	243,134	–	–	0.32%	17
2023 Q1	$277K	Hold	243,134	–	–	0.25%	20
2022 Q4	$219K	Hold	243,134	–	–	0.18%	22
2022 Q3	$284K	Hold	243,134	–	–	0.23%	20
2022 Q2	$156K	Hold	243,134	–	–	0.13%	22
2022 Q1	$635K	Hold	243,134	–	–	0.41%	17
2021 Q4	$946K	Hold	243,134	–	–	0.59%	14
2021 Q3	$1.06M	Hold	243,134	–	–	0.66%	12
2021 Q2	$965K	Buy	+243,134	New	+$971K	0.61%	12

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Latash Investments's AQST Position: Q2 2026 in Review

Latash Investments held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 243,134 shares worth $1.01M. The position accounts for 0.74% of the portfolio, ranked #7.

Latash Investments first reported a position in AQST in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.57M in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Latash Investments held 243,134 shares of Aquestive Therapeutics worth $1.01M as of Q2 2026.
Latash Investments left its Aquestive Therapeutics share count unchanged in Q2 2026.
Aquestive Therapeutics made up 0.74% of Latash Investments's portfolio in Q2 2026, its #7 holding.
Latash Investments first reported a position in Aquestive Therapeutics in Q2 2021 and has held it in 21 quarters since.
Latash Investments's Aquestive Therapeutics position peaked at $1.57M in Q4 2025.
185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Latash Investments's 13F filing for Q2 2026, filed 11 Aug 2026.